Early Alzheimer's Tied to Rest-Activity Rhythm Fragmentation
TUESDAY, Jan. 30, 2018 -- Preclinical Alzheimer's disease (AD) and aging are independently associated with rest-activity rhythm fragmentation among cognitively normal adults, according to a study published online Jan. 29 in JAMA Neurology.
Erik S. Musiek, M.D., Ph.D., from the Washington University School of Medicine in St. Louis, and colleagues conducted a cross-sectional study involving 205 cognitively normal volunteers who underwent seven to 14 days of actigraphy in their home environment. Participants also underwent clinical assessment, amyloid imaging with Pittsburgh Compound B (PiB), and cerebrospinal fluid biomarker collection. Due to incomplete data collection, 16 participants were excluded.
The researchers found that in the absence of amyloid pathology, older age and male sex were associated with a significant increase in intradaily variability, a nonparametric measure of rest-activity rhythm fragmentation, and with decreased amplitude by several measures. The presence of preclinical amyloid plaque pathology, as assessed by positive PiB imaging or increasing cerebrospinal fluid phosphorylated-tau to amyloid β 42 ratio, was correlated with increased intradaily variability after adjustment for age and sex.
"The presence of circadian rhythm abnormalities in the preclinical phase of AD suggests that circadian dysfunction could contribute to early disease pathogenesis or serve as a biomarker of preclinical disease," the authors write.
Two authors disclosed financial ties to the biopharmaceutical industry. The study was funded in part by Philips Respironics.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.